Featured Story | By Nick Paul Taylor AstraZeneca has talked up the prospects of its anti-SARS-CoV-2 antibody working in severe COVID-19 patients despite rival assets from Eli Lilly and Regeneron failing in that population. Mene Pangalos, an AstraZeneca EVP, made the comments while sharing news the antibody is set to start a prophylaxis study next week. read more |
| |
|---|
|
|  | For oncology CROs, the utilization of noninvasive optical imaging gives researchers an earlier indication of anti-cancer activity and valuable insight into the effects of new drugs. Our free white paper details its benefits and how this method can advance your drug program. Read more! |
Top Stories By Amirah Al Idrus Experts and industry watchers fully expect the FDA to approve Biogen’s controversial Alzheimer’s drug aducanumab—but not because it’s a game changer. In the words of one analyst, aducanumab won’t get the agency’s nod because its data are strong, but rather “in spite of the quality” of those data. read more By Nick Paul Taylor Humanigen has estimated its anti-GM-CSF antibody caused 37% more recoveries than standard of care in hospitalized COVID-19 patients. The data remain blinded, but Humanigen calculated the effect of the drug based on the changes to enrollment requested by the data safety monitoring board. read more Sponsored By: WCG Are you looking to optimize your site’s patient recruitment advertising dollars? WCG’s experienced team of patient recruitment experts can help your site efficiently use your advertising funds by creating customized recruitment campaigns for any of your studies, and we’ve also curated a list of best practices to ensure your spend sees the best ROI. read more By Ben Adams Assembly Bio was hoping its experimental hepatitis B drug could be a functioning cure for the viral liver disease, but a midstage flop has seen the biotech rethink this path in the near term. read more By Amirah Al Idrus Bristol Myers Squibb was already working on a plan to boost diversity in clinical trials, but the events of 2020—namely a pandemic that disproportionately affects minorities and a social justice movement reignited by the murder of George Floyd—ramped up its efforts. read more By Arlene Weintraub Could a single gene reduce our craving for sugary foods while at the same time increasing our desire to exercise? NIH researchers reported that knocking out a gene called Prkar2a in mice caused the animals to cut their consumption of high-fat foods and increased their motivation to exercise. read more By Angus Liu AstraZeneca's sales suffered in the third quarter because of a COVID-19-related slowdown of Pulmicort in China. Novartis established its first CAR-T facility in Asia. China's Clover Biopharma won a $258 million grant from CEPI for its COVID-19 vaccine work. And more. read more By Conor Hale Novartis alums Jimenez, Fishman unveil their next act, Deep Genomics nabs a CBO from Synlogics, and Santhera's CMO hits the exit. read more Resources Sponsored By: Medidata Responding to site challenges. Approaching virtualization. Leveraging real-time data. Medidata shares 8 parameters to implement your virtualization strategy during COVID-19 and beyond. Download Now. Sponsored By: WCG Need additional site resources for your current or upcoming clinical trial? Sponsored By: AmerisourceBergen How pharma's supply chain partners are paving the way for coronavirus therapies. Sponsored By: Lonza Liquid-filled hard capsule formulations offer unique options for the manufacture and dosing of highly potent actives. Sponsored By: Thermo Fisher Scientific Anticipate early development challenges to avoid rework and costs. Sponsored By: Cytiva Accelerating the production of viral-vector based therapy requires both understanding of strategies to address viral vector manufacturing and how to select the most cost-effective solution for your therapeutic. Read more in this article. Sponsored by: LexisNexis Risk Solutions Get insights into healthcare decision-makers networks. Sponsored By: Veeva Learn how to plan immersive digital event experiences Sponsored by: Aldevron Gene and cell therapy organizations are asked to balance the need for rapid clinical progression and stringent quality expectations throughout development. In this document, Aldevron provides an in-depth look at preparing for plasmid manufacturing based on our years of experience. Sponsored By: Elligo Health Research® Understanding the Challenges COVID-19 Pediatric Clinical Trials Face | White Paper Sponsored By: Outer Edge Technology A sound Cloud Strategy provides the flexibility and tools businesses need to quickly adapt and operate securely in an ever-changing remote work environment. Learn how your company can cost-effectively empower its employees to be productive and secure while working remotely. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Cascade Chemistry, API CDMO Struggling with complex chemistry to get APIs for clinical trials? Find out what to look for in an API CDMO partner to gain expertise and speed that lead to success. Sponsored by: Catalent Learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools. Sponsored by: Catalent This eBook provides insights on key approaches and considerations for preparing your drug development program for long-term success. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. Sponsored by: Formedix Learn how to save time and reduce costs and complexity by streamlining the clinical trial process. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
